Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Nat Biotechnol. 2011 Jan;29(1):73-8. doi: 10.1038/nbt.1717. Epub 2010 Dec 12.

    Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells.

    Source

    Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

    Abstract

    Realizing the therapeutic potential of human induced pluripotent stem (iPS) cells will require robust, precise and safe strategies for genetic modification, as cell therapies that rely on randomly integrated transgenes pose oncogenic risks. Here we describe a strategy to genetically modify human iPS cells at 'safe harbor' sites in the genome, which fulfill five criteria based on their position relative to contiguous coding genes, microRNAs and ultraconserved regions. We demonstrate that ∼10% of integrations of a lentivirally encoded β-globin transgene in β-thalassemia-patient iPS cell clones meet our safe harbor criteria and permit high-level β-globin expression upon erythroid differentiation without perturbation of neighboring gene expression. This approach, combining bioinformatics and functional analyses, should be broadly applicable to introducing therapeutic or suicide genes into patient-specific iPS cells for use in cell therapy.

    Comment in

    • Out of harm's way. [Nat Biotechnol. 2011]
    PMID:
    21151124
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3356916
    Free PMC Article

    Images from this publication.See all images (3)Free text

    Figure 1
    Figure 2
    Figure 3

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk